Gain Therapeutics (NASDAQ:GANX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 351.98% from the company’s previous close. GANX has [...]
Gain Therapeutics (NASDAQ:GANX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 351.98% from the company’s previous close. GANX has [...]This article was originally published by Daily Political.
Read Full Story on Source Site →
